Trials / Terminated
TerminatedNCT01796470
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy of the combination entospletinib and idelalisib in participants with relapsed or refractory hematologic malignancies. Participants will be enrolled who have one of the following hematological tumor types: chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), or indolent non-Hodgkin lymphomas (iNHL; including follicular lymphoma (FL) and lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia \[LPL/WM\], small lymphocytic lymphoma \[SLL\], or marginal zone lymphoma \[MZL\]).
Conditions
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Diffuse Large B-cell Lymphoma
- Indolent Non-Hodgkin's Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Entospletinib | Entospletinib tablets administered orally twice daily |
| DRUG | Idelalisib | Idelalisib tablets administered orally twice daily |
Timeline
- Start date
- 2013-06-20
- Primary completion
- 2015-01-01
- Completion
- 2016-12-22
- First posted
- 2013-02-21
- Last updated
- 2020-06-02
- Results posted
- 2020-06-02
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01796470. Inclusion in this directory is not an endorsement.